Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Preservation group sues Trump administration over White House...
House GOP unveils healthcare plan ahead of vote...
Cruz says Rep Ilhan Omar could face jail...
Republican House leader signals plan to begin contempt...
MIKE DAVIS: Why DC’s Trump-hating Judge Boasberg must...
State Department stays quiet as Albania reinstates deputy...
Maduro trapped with few retaliation options after Trump...
Sun Summit Announces Upsized Non-Brokered Private Placement of...
InMed Provides Update on BayMedica Commercial Business
Contango ORE, Dolly Varden Announce Strategic Silver Merger
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Business

Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

by admin September 8, 2025
September 8, 2025
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

Shares of Kenvue fell more than 10% on Friday after a report that Health Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company’s pain medication Tylenol in pregnant women.

HHS will release the report that could draw that link this month, The Wall Street Journal reported on Friday.

That report will also suggest a medicine derived from folate — a water-soluble vitamin — can be used to treat symptoms of the developmental disorder in some people, according to the Journal.

In a statement, an HHS spokesperson said, “We are using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates.”

“Until we release the final report, any claims about its contents are nothing more than speculation,” they added.

Tylenol could be the latest widely used and accepted treatment that Kennedy has undermined at the helm of HHS, which oversees federal health agencies that regulate drugs and other therapies. Kennedy has also taken steps to change vaccine policy in the U.S., and has amplified false claims about safe and effective shots that use mRNA technology.

Kennedy has made the disorder a key focus of HHS, pledging in April that the agency will “know what has caused the autism epidemic” by September and eliminate exposures. He also said that month that the agency has launched a “massive testing and research effort” involving hundreds of scientists worldwide that will determine the cause.

In a statement, Kenvue said it has “continuously evaluated the science and [continues] to believe there is no causal link” between the use of acetaminophen, the generic name for Tylenol, during pregnancy and autism.

The company added that the Food and Drug Administration and leading medical organizations “agree on the safety” of the drug, its use during pregnancy and the information provided on the Tylenol label.

The FDA website says the agency has not found “clear evidence” that appropriate use of acetaminophen during pregnancy causes “adverse pregnancy, birth, neurobehavioral, or developmental outcomes.” But the FDA said it advises pregnant women to speak with their health-care providers before using over-the-counter drugs.

The American College of Obstetricians and Gynecologists maintains that acetaminophen is safe during pregnancy when taken as directed and after consulting a health-care provider.

Some previous studies have suggested the drug poses risks to fetal development, and some parents have brought lawsuits claiming that they gave birth to children with autism after using it.

But a federal judge in Manhattan ruled in 2023 that some of those lawsuits lacked scientific evidence and later ended the litigation in 2024. Some research has also found no association between acetaminophen use and autism.

In a note on Friday, BNP Paribas analyst Navann Ty said the firm believes the “hurdle to proving causation [between the drug and autism] is high, particularly given that the litigation previously concluded in Kenvue’s favor.”

This post appeared first on NBC NEWS

previous post
Top Biden officials questioned and criticized how his team issued pardons, used autopen: report
next post
Juggernaut Samples up to 256.60 g/t Or 8.25 oz/t Gold and Identifies 4 New Gold-Rich Zones that Remain Wide Open and are Drill Ready within the Highway of Gold Corridor on the Big One Property, Golden Triangle, B.C.

You may also like

Nvidia’s CEO did a Q&A with analysts. What...

March 25, 2025

Target CEO to meet with Rev. Al Sharpton...

April 18, 2025

Disney debuts its latest cruise ship, Treasure, as...

November 21, 2024

Businesses are cautiously spending on corporate travel as...

July 24, 2025

Top liquor distributor favored Costco and Kroger over...

December 14, 2024

How Foot Locker is waging a comeback after...

September 24, 2024

Donatella Versace steps down as head of Italian...

March 14, 2025

Trader Joe’s recalls 653,000 scented candles due to...

August 16, 2024

Tesla’s law firm drafts Delaware bill that could...

February 19, 2025

Google has eliminated 35% of managers overseeing small...

August 28, 2025

Recent Posts

  • Preservation group sues Trump administration over White House ballroom project
  • House GOP unveils healthcare plan ahead of vote next week as cost hike looms for millions
  • Cruz says Rep Ilhan Omar could face jail time, deportation if marriage allegation proves true
  • Republican House leader signals plan to begin contempt proceedings against Bill and Hillary Clinton
  • MIKE DAVIS: Why DC’s Trump-hating Judge Boasberg must be impeached

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (963)
    • Investing (3,656)
    • Politics (4,414)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.